{
    "NCT05979779": {
        "model_response": [
            "Sure! In the experimental arm, the participants will receive the active treatment of HU6. The intervention will be in the form of a drug product that can be taken orally, such as a tablet or capsule. The participants in the control arm will receive the placebo, which will be similar in appearance to the active treatment but will be inactive. Both placebo and treatment will be taken orally in the forms of tablets or capsules. The dose of HU6 will be divided into 57 different levels. You can use a single-arm design to compare the effects of these different dose levels of HU6 within the experimental arm. This single-arm study design will consist of 9 periods, each of which will focus on different dosages of HU6, and all participants will receive one of these dosages in each period. The order of the dosages will be determined by a randomization list. The dose amounts will increase from the first period to the last period. Here's a sample timeline:",
            "The comparator arm will be called \"Placebo Comparator: Placebo.\" The participants in this arm will also be obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis. They will receive placebo. The primary purpose of this arm is to determine if the results observed in the HU6 group were really due to the HU6 or whether any observed improvements are merely due to placebo.",
            "Precisely. The participants will be randomly assigned to receive either the active medication, HU6, or the placebo comparator group, allowing comparisons between the two groups. Randomized allocation will assign participants to treatment based on a prespecified protocol, and blinding will mask the allocation to prevent bias in the assessment of outcomes."
        ],
        "eval_results": [
            "Match prediction: 1\n\nExplanation:\nThe study arms mentioned in the model's output, which are the \"Experimental: Active Treatment: HU6\" arm and the \"Placebo Comparator: Placebo Comparator\" arm, are fully present in the groundtruth study arm table. The model's output accurately describes the interventions and treatments for these two study arms, which match the information provided in the groundtruth table.",
            "Match prediction: 1\n\nExplanation:\nThe study arms mentioned in the model's output, \"Placebo Comparator: Placebo\", are fully included in the groundtruth study arm table. The groundtruth table clearly shows a \"Placebo Comparator: Placebo Comparator\" arm, which matches the description provided in the model's output. Additionally, the description of the participants in the placebo comparator arm, \"obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis\", also aligns with the information provided in the groundtruth table.",
            "Match prediction: 1\n\nExplanation:\nThe study arms mentioned in the model's output, \"Control: Placebo\" and \"Experimental: Active Treatment: HU6\", are fully present in the groundtruth study arm table. The groundtruth table includes the \"Placebo Comparator: Placebo Comparator Non-active study drug\" arm, which corresponds to the \"Control: Placebo\" arm mentioned in the model's output. Similarly, the groundtruth table includes the \"Experimental: Active Treatment: HU6 Planned doses of HU6\" arm, which corresponds to the \"Experimental: Active Treatment: HU6\" arm mentioned in the model's output. Therefore, the study arms from the model's output are fully included in the groundtruth study arm table, and the match prediction is '1'."
        ]
    }
}